CLARIVATE PLC (CLVT): what the price requires

At today's price, CLARIVATE PLC (CLVT) is priced for today's economics sustained for ~9.0 years. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high.

Generated: 2026-07-19 · Source: https://boothcheck.com/report/CLVT

Headline

FieldValue
TickerCLVT
CompanyCLARIVATE PLC
Current price$2.24/sh
CompositionSubscription 65% / Re-occurring 18% / Transactional 17%

What The Price Requires (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basiswhole-company
Operating margin needed11.4%
Operating margin today2.5%
Margin expansion implied+8.9pp
Must persist for9.0y
Multiple paid94x operating income

The operating-margin requirement is derived from the framework's value band at year 12, a separately labeled basis from the headline growth/duration solve.

Solve inputs: computed at a 7% cost of capital; growth searched up to the 25% self-funding ceiling; each 1pp moves the implied horizon ~2.7 years (computed at the 7% minimum rate; the CAPM rate 7% sits below it).

Reconcile: at the x-ray's 9.3% required return this reads ~14.5 years; the models below use their own rates.

How unusual the bet is: elevated

ReferenceValue
vs own history+0.56σ
sustained it ~9 years at this level17%
implied end-window share0%

Valuation X-Ray

The price is supported by asset-based and relative-multiple value. A value/asset-supported name, not a pure growth bet.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset0.33x3justifies
Earnings—0—
Relative0.08x2justifies
Growth—0—

Families that justify the price: Asset, Relative

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 5.3%); the inversion above states its own rate.

Per-Model Detail (n=5)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth$3.270.68xnoFCF base $0.3B, growth -3% (input: historical growth), terminal g 0.5%, WACC 5.3%, 5yr projection
DCF Exit MultipleGrowth$3.130.71xnoExit EV/EBITDA: 4.3x / 6.3x / 8.3x (bear / base = today's held flat / bull), 5yr
Relative ValuationRelative$30.550.07xyesP/S fallback (negative EPS): Sector P/S 8.0x × TTM revenue — excluded from consensus
Simple DDMGrowth——no—
Two-Stage DDMGrowth——no—
Simple Excess ReturnAsset$7.470.30xyesReference only (book value floor): BV/sh $7.47, ROE negative
Two-Stage Excess ReturnAsset$6.730.33xyesReference only (book value with convergence): BV/sh $7.47, ROE converges to ke
Discounted Future Market CapGrowth$1.281.75xnoRev $2.4B, growth -3% (input: historical growth; tapered), Terminal P/S: 0.5x / 0.6x / 0.7x (bear / base = today's held flat / bull, cap 8x)
Peter Lynch Fair ValueRelative$0.00—noNegative/zero EPS — earnings-based value floored at $0
Margin TrajectoryGrowth——no—
Earnings Power ValueEarnings——no—
Residual IncomeAsset——no—
Graham NumberAsset——no—
EV/EBITDA RelativeRelative$27.890.08xyesEBITDA $0.88B × sector EV/EBITDA 25.0x
FCF YieldEarnings$0.01223.50xyesFCF $333.9M / Kₑ 9.3% — zero-growth perpetuity (excluded from median)
SBC-Adj FCF YieldEarnings$0.01223.50xyesSBC-adj FCF $0.27B (FCF $0.33B − SBC $0.07B) capitalized at Kₑ (excluded from median)
Ben Graham FormulaEarnings——no—
ROIC-Justified P/BAsset$0.385.88xyesBV $7.47 × (ROIC 0.3% / WACC 5.3%)
P/Sales SectorRelative$30.550.07xnoRevenue $2.45B × sector P/S 8.0x
PEG Fair ValueRelative——no—
Earnings YieldEarnings——no—
Funds From Operations MultipleRelative——no—
Clinical Phase NPVGrowth——no—
MertonAsset——no—
V5 Mechanical———no—

Solvency

FieldValue
Net debt$4.2b
Net debt / NOPAT (after-tax)87.76x
Net debt / operating income (pre-tax)69.33x
Share count CAGR (buyback)-1.8%
Burning cashno

Interest expense is not separately reported in the latest filings, so interest coverage cannot be computed.

Bullet Takeaways

Bull Case

The bull case rests on the balance sheet being managed toward the equity rather than away from it, and the recent record supports that. Clarivate generates real free cash flow, guided to grow about 10% to roughly $400 million for the full year, and it is pointing that cash at its debt: management completed the redemption of its remaining 2026 secured notes and projects retiring its secured notes ahead of the 2028 maturity using free cash flow. A leveraged business that throws off cash and is actually paying down debt is doing the one thing that transfers value from creditors to shareholders. The share count has even edged lower rather than higher, the opposite of the dilution that defines distressed names.

The asset underneath is a recurring-revenue franchise that the price is treating as if it were broken. Roughly 65% of revenue is subscription and another 18% recurs, and the turnaround is showing up in the leading indicators: renewal rates improved about 100 basis points and organic subscription revenue grew 1.7% in the first quarter, the fifth consecutive quarter of improved performance under the Value Creation Plan, with adjusted EBITDA margin reaching 41% and guided toward nearly 43% for the year. High-margin, renewing data subscriptions are a genuinely good business model; FactSet, a peer in the same data-and-analytics cohort, describes its own Annual Subscription Value as the metric that "reflects our ability to grow recurring revenues and generate positive cash flows", and Verisk notes that roughly "83%" of its revenue is subscription. Clarivate has the same shape, just at a depressed valuation.

That depressed valuation is the bull's clearest point. Every asset-based and sales-based method lands well above the price. Book value is around $7.47 a share against a price near $2, and on a sector sales multiple the business prices many times higher than where it trades. When the asset and relative-multiple frames both say the price is low, this is not a growth bet that needs everything to go right; it is a value situation where the market is pricing continued decline, and the turnaround only has to keep grinding renewal rates and margins higher to close the gap. If the potential Life Sciences and Health divestiture lands at a fair price, the proceeds go straight at the debt, and the equity sliver gets thicker fast.

Bear Case

The structural truth a holder has to face is that Clarivate is cheap for a reason: the underlying business has been shrinking, and the debt magnifies every wobble. Strip away the turnaround narrative and the GAAP picture carries distress signals, sustained net losses, negative retained earnings, and a balance sheet read that flags financial stress. Full-year revenue is guided to fall by roughly $100 million to about $2.36 billion, and while management attributes the decline to disposals, the organic growth that remains is slow: subscription revenue grew 1.7% and the Intellectual Property segment's organic trends are still near flat. A data business whose recurring revenue grows in the low single digits is not compounding; it is treading water, and treading water under leverage is a precarious place to stand.

The leverage is the bear's core. Net debt of about $4.2 billion sits against only roughly $242 million of liquid assets, and interest expense is not even separately broken out cleanly in the filings, which makes coverage hard to verify. The equity at today's price is a thin claim on top of a large pile of debt; in a leveraged capital structure, the equity is the most volatile piece, gaining disproportionately if the turnaround works and getting crushed if it stalls. The market's own valuation reflects exactly this: the price sits well below book value, which is the market saying it does not believe the assets are worth their carrying value to equity holders after the debt is served.

The competitive context makes the slow growth more worrying, not less. Clarivate's best-in-class peers are growing the same kind of recurring revenue far faster: FactSet reported organic Annual Subscription Value up 5.7%, several times Clarivate's subscription pace, and the gap is the tell. In subscription data, share and renewal momentum compound, so a franchise growing at a third of its peers' rate is slowly losing relative ground even as it stabilizes in absolute terms. The bull's turnaround needs renewal rates and margins to keep improving for years against that backdrop. If the Value Creation Plan plateaus, or if a Life Sciences sale comes at a disappointing price, the equity behind $4.2 billion of net debt is where the disappointment lands first.

Valuation

Clarivate is the rare name where the methods split cleanly, and the split is the whole story. On its assets and on its sales, the business looks cheap: book value sits around $7.47 a share against a price near $2, and a sector sales multiple applied to its revenue prices the enterprise many times above where the equity trades. The asset-based and relative-multiple frames both place value well above the price, which is why this reads as a value or asset-supported situation rather than a growth bet. The same methods that flag overvaluation in most reports are pointing the other way here.

What complicates the value read is the leverage and the GAAP distress. The standard cash-flow and earnings projection methods fall away because the company carries distress signals, sustained losses and negative retained earnings, so the projection-based frames cannot run honestly. That leaves the asset and sales lenses doing the work, and they say the same thing: the enterprise is worth more than the market assigns to the equity, but a heavily indebted enterprise hands most of that value to creditors first. Worked backward, the price embeds company-wide operating growth held near its ceiling for roughly nine years, and the company's recent pace is within that rate; the stretch is the duration, not the speed. For a turnaround that is five quarters into grinding renewal rates higher, that is a less heroic assumption than it sounds.

Solvency is therefore the binding question, and it cuts both ways. Net debt of about $4.2 billion against roughly $242 million of liquid assets is the weight; free cash flow guided toward $400 million pointed at debt reduction is the lever working against it. There is no dilution amplifier here, the share count is flat to slightly lower, which matters because it means the cash flow accrues to a stable equity base. The decisive variable is whether the recurring-revenue base stabilizes and the potential Life Sciences and Health divestiture lands at a price that meaningfully cuts the debt. The asset and sales methods say the value is there; the balance sheet decides how much of it reaches the equity.

Catalysts

The turnaround cadence is the recurring catalyst. The first quarter of 2026 marked the fifth consecutive quarter of improved performance under the Value Creation Plan, with revenue of $586 million, adjusted EBITDA of $241 million at a 41% margin, organic subscription revenue up 1.7%, and renewal rates improving about 100 basis points. Each quarter that extends the streak builds the case that the recurring base has stabilized; a single quarter that breaks it would reopen the decline thesis.

The capital-structure catalysts are concrete and value-relevant. Clarivate redeemed the remaining $100 million of its 4.50% senior secured notes due 2026 in February 2026 and guides full-year free cash flow to grow about 10% to roughly $400 million, with management projecting full retirement of its secured notes ahead of the 2028 maturity from internal cash. For a leveraged equity, debt reduction is the most direct catalyst there is.

The largest discrete catalyst is the potential divestiture of the Life Sciences and Health business. Company guidance currently assumes continued ownership, with management noting that a sale agreement would require a guidance revision later in the year. A sale at a fair price would convert a slower-growth segment into proceeds aimed at the debt, reshaping both the growth profile and the balance sheet. Analyst sentiment remains cautious, a Hold consensus with a price target near $3.22 as of mid-2026, which sits above the current price and reflects the market crediting the stabilization without yet underwriting the full turnaround.

Peer Cohorts (Per Segment, With Filing Citations)

Academia & Government (reported)

Intellectual Property (reported)

Life Sciences & Healthcare (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

Sources

company FY2026 guidance and refinancing disclosures · Q1 2026 earnings release · FDS FY2025 10-K · company refinancing and FY2026 guidance disclosures · company FY2026 guidance commentary · analyst notes, 2026

View the full interactive CLVT report on boothcheck